ADMA Biologics Inc (NASDAQ:ADMA) CFO Brian Lenz acquired 6,500 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was purchased at an average cost of $2.15 per share, for a total transaction of $13,975.00. Following the transaction, the chief financial officer now owns 15,000 shares in the company, valued at $32,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
ADMA Biologics Inc (NASDAQ ADMA) traded up $0.16 during mid-day trading on Tuesday, reaching $2.48. 239,100 shares of the company were exchanged, compared to its average volume of 51,671. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics Inc has a one year low of $2.01 and a one year high of $6.88.
ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.29). The company had revenue of $3.40 million during the quarter, compared to analyst estimates of $3.52 million. ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. equities research analysts forecast that ADMA Biologics Inc will post -2.25 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/11/14/adma-biologics-inc-adma-cfo-brian-lenz-purchases-6500-shares.html.
A number of research analysts have recently issued reports on the stock. Raymond James Financial, Inc. raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.